103 related articles for article (PubMed ID: 36219195)
1. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J; Cordero A; Olmo RF; Cortez Quiroga GA; Fácila L; Salgado-Barreira Á; Reyes-Santías F; Romero-Menor C; Murillo JR; Rodríguez-Mañero M; Bello Mora MC; Valle A; Sandin M; Pamias RF; Bañeras J; García PB; Lorenzo MC; Sánchez-Alvarez S; López-Rodríguez L; González-Juanatey JR
J Cardiovasc Pharmacol; 2023 Jan; 81(1):70-75. PubMed ID: 36219195
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
[TBL] [Abstract][Full Text] [Related]
3. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
4. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol lowering treatment: the current approach.
Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
[TBL] [Abstract][Full Text] [Related]
6. Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
Cosín-Sales J; Campuzano Ruiz R; Díaz Díaz JL; Escobar Cervantes C; Fernández Olmo MR; Gómez-Doblas JJ; Mostaza JM; Pedro-Botet J; Plana Gil N; Valdivielso P
Atherosclerosis; 2023 Jun; 375():38-44. PubMed ID: 37245425
[TBL] [Abstract][Full Text] [Related]
7. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors.
Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C
J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601
[TBL] [Abstract][Full Text] [Related]
8. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
Banach M; Penson PE; Farnier M; Fras Z; Latkovskis G; Laufs U; Paneni F; Parini P; Pirro M; Reiner Ž; Vrablik M; Escobar C
Prog Cardiovasc Dis; 2023; 79():2-11. PubMed ID: 36889490
[TBL] [Abstract][Full Text] [Related]
9. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
Doggrell SA
Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
[TBL] [Abstract][Full Text] [Related]
10. Role of PCSK9 inhibitors in the management of dyslipidaemia.
Nair T
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S44-S50. PubMed ID: 38195006
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
[TBL] [Abstract][Full Text] [Related]
12. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.
Ebenbichler C; Drexel H; Hanusch U; Toplak H; Dhalwani NN; Bridges I; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2024 Feb; 136(3-4):77-86. PubMed ID: 37525072
[TBL] [Abstract][Full Text] [Related]
13. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract][Full Text] [Related]
14. LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study.
Katzmann JL; Stürzebecher PE; Kruppert S; Laufs U
Sci Rep; 2024 Jan; 14(1):474. PubMed ID: 38172531
[TBL] [Abstract][Full Text] [Related]
15. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Covington AM; DePalma SM; Minissian MB; Orringer CE; Smith SC; Waring AA; Wilkins JT
J Am Coll Cardiol; 2022 Oct; 80(14):1366-1418. PubMed ID: 36031461
[No Abstract] [Full Text] [Related]
16. [Update on lipid lowering therapy in peripheral artery disease].
Mühlberg KS
Dtsch Med Wochenschr; 2023 Nov; 148(22):1406-1411. PubMed ID: 37918423
[TBL] [Abstract][Full Text] [Related]
17. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress.
Gupta K; Hinkamp C; Andrews T; Meloche C; Minhas AMK; Slipczuk L; Vaughan E; Habib FZ; Sheikh S; Kalra D; Virani SS
Curr Atheroscler Rep; 2023 Dec; 25(12):965-978. PubMed ID: 37975955
[TBL] [Abstract][Full Text] [Related]
18. [Bempedoic acid, a new cholesterol-lowering agent].
Oostindjer A; Roeters van Lennep JE
Ned Tijdschr Geneeskd; 2023 Nov; 167():. PubMed ID: 38175561
[TBL] [Abstract][Full Text] [Related]
19. [Update lipidology : Evidence-based treatment of dyslipidemia].
Parhofer KG
Inn Med (Heidelb); 2023 Jul; 64(7):611-621. PubMed ID: 37318557
[TBL] [Abstract][Full Text] [Related]
20. Impact of Bempedoic acid on LDL-C reduction and cardiovascular outcomes: A comprehensive meta-analysis of randomized controlled trials.
Del Carpio-Tenorio C; Llerena-Velastegui J; Villacis-Lopez C; Placencia-Silva M; Santander-Fuentes C; Benitez-Acosta K; Sanahuja-Montiel C; Dominguez-Gavilanes D; Carrasco-Perez P; Calderon-Lopez C
Curr Probl Cardiol; 2024 Feb; 49(2):102191. PubMed ID: 37981266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
